PD-1/PD-L1抑制剂联合含铂方案化疗治疗晚期肺癌不良反应的研究进展  

Research progress of PD-1/PD-L1 inhibitor combined with platinum-based chemotherapy in the treatment of adverse reactions of advanced lung cancer

作　　者：吴春娃[1] 李凯[2] 张翠翠[2] WU Chun-wa;LI Kai;ZHANG Cui-cui(Department of oncology,Tianjin Beichen hospital,Tianjin 300400,China;不详)

机构地区：[1]天津市北辰医院肿瘤科,天津300400 [2]天津医科大学附属肿瘤医院肺部肿瘤内科,天津300060

出　　处：《中国处方药》2021年第4期25-27,共3页Journal of China Prescription Drug

基　　金：国家自然科学基金青年科学基金项目(81802296)。

摘　　要：长期以来,治疗无EGFR及ALK敏感基因突变的晚期非小细胞肺癌及小细胞肺癌的一线治疗方案主要为含铂的双药化疗。然而近年来,随着PD-1/PD-L1免疫抑制剂的问世,肺癌的治疗方式发生了很大的变化。PD-1/PD-L1免疫抑制剂单独用于治疗晚期非小细胞肺癌取得了较好的疗效,而一系列随机对照临床试验证实了PD-1/PD-L1免疫抑制剂联合含铂方案化疗较单纯化疗有更好的临床疗效。但抗肿瘤免疫反应的激活可能导致一系列的免疫相关不良反应,其与铂类化疗不良反应的处理原则有很大区别。通过对铂类联合免疫检查点抑制剂治疗晚期肺癌的临床试验的研究,没有证据表明抗PD-(L)1药物与铂类化疗的联合应用会增加不良反应的严重程度或导致意外毒性。For a long time,the first-line treatment for advanced non-small cell lung cancer and small cell lung cancer without EGFR and ALK sensitive gene mutations has been mainly platinum-based dual-drug chemotherapy.However,in recent years,with the advent of PD-1/PD-L1 immunosuppressants,the treatment of lung cancer has undergone great changes.PD-1/PD-L1 immunosuppressants were used alone to treat advanced non-small cell lung cancer and achieved good results,and a series of randomized controlled clinical trials have confirmed that PD-1/PD-L1 immunosuppressant combined with platinumbased chemotherapy has better clinical efficacy than chemotherapy alone.However,the activation of the anti-tumor immune response may lead to a series of immune-related adverse events(AEs),which are very different from the treatment principles of platinum-based chemotherapy.Through clinical trials of platinum-based immune checkpoint inhibitors in the treatment of advanced lung cancer,there is no evidence that the combined application of anti-PD-(L)1 drugs and platinum-based chemotherapy will increase the severity of adverse reactions or cause unexpected toxicity.

关 键 词：免疫相关不良反应 程序性死亡受体1 程序性死亡配体1 晚期肺癌 含铂化疗 

分 类 号：R969.3[医药卫生—药理学]